Management of Hypertrophic Cardiomyopathy – ACC/AHA Guideline Summary
Pharmacologic Management of Obstructive HCM
- First‑line therapy: Non‑vasodilating β‑blockers are a Class I recommendation for all symptomatic patients with obstructive HCM; they should be titrated to a resting heart rate of 60–65 bpm to reduce LVOT gradients and improve symptoms. 1
- Verapamil contraindications: Verapamil should be avoided in patients with severe resting dyspnea, hypotension, very high resting gradients > 100 mm Hg, and in infants younger than 6 weeks. 1
- Second‑line option before septal reduction: Disopyramide combined with an AV‑nodal blocking agent (β‑blocker or non‑dihydropyridine calcium‑channel blocker) is recommended for patients who remain severely symptomatic despite optimal first‑line therapy. 1
- Medication to avoid: Digoxin is a Class III (harm) agent in obstructive HCM and should be discontinued. 1
Acute Hemodynamic Management
- Hypotension unresponsive to fluids: Intravenous phenylephrine (or another pure vasoconstrictor without inotropic activity) is recommended, alone or with a β‑blocker, for acute obstructive HCM with hypotension. 1
- Volume overload: Low‑dose oral diuretics may be used cautiously when persistent dyspnea is accompanied by clinical evidence of volume overload despite guideline‑directed therapy. 1
Septal Reduction Therapy
- Indications (Class I):
- Center expertise: Procedures must be performed at experienced comprehensive or primary HCM centers with proven excellence in outcomes. [2][4]
- Contraindications (Class III harm):
Pharmacologic Management of Non‑Obstructive HCM
- Symptom relief: β‑blockers or non‑dihydropyridine calcium‑channel blockers are recommended for exertional angina or dyspnea. [2][5]
- Adjunct diuretic therapy: Oral diuretics should be added when dyspnea persists despite the above agents. [2][5]
- Renin‑angiotensin system blockers: ACE inhibitors and ARBs have uncertain benefit for symptom relief in non‑obstructive HCM. [2][5]
- Asymptomatic patients: Routine use of β‑blockers or calcium‑channel blockers is not supported in asymptomatic non‑obstructive HCM. [2][5]
Atrial Fibrillation Management
- Universal anticoagulation: All HCM patients with atrial fibrillation (clinical or subclinical > 24 h) require anticoagulation regardless of CHA₂DS₂‑VASc score. [2][5]
- Preferred agents: Direct‑acting oral anticoagulants (DOACs) are first‑line; vitamin K antagonists are second‑line. [2][5]
- Rate control: β‑blockers, verapamil, or diltiazem may be used for ventricular rate control. 5
Sudden Cardiac Death (SCD) Risk Stratification
- Major non‑invasive risk markers (Class I):
- Risk‑based ICD decision: In patients > 16 years, a 5‑year SCD risk estimate can guide shared decision‑making for primary‑prevention ICD placement. 1
Lifestyle and Activity Recommendations
- Shared decision‑making: Individualized physical‑activity plans should be developed through shared decision‑making, balancing SCD risk with quality‑of‑life benefits. 4
Multidisciplinary Care and Referral
- Referral to specialized HCM centers (reasonable): For complex management—including interpretation of genetic testing, primary‑prevention ICD decisions, and evaluation for septal reduction therapy—referral to comprehensive or primary HCM centers is advised. [4][5]
Initial Management of Hypertrophic Cardiomyopathy
First-Line Pharmacological Management
- The American College of Cardiology recommends nonvasodilating beta-blockers as first-line therapy for symptomatic patients with hypertrophic cardiomyopathy, titrated to a resting heart rate of 60-65 bpm, with the goal of reducing symptoms and improving quality of life 6, 7
- Nonvasodilating beta-blockers are the Class I recommended initial treatment for all symptomatic HCM patients, regardless of whether obstruction is present, according to the American College of Cardiology 6, 7
- Beta-blockers reduce left ventricular outflow tract (LVOT) gradients, alleviate dyspnea, and improve quality of life in patients with hypertrophic cardiomyopathy 6
Second-Line Pharmacological Options
- The American College of Cardiology recommends mavacamten, a cardiac myosin inhibitor, as a Class I option for adults with persistent NYHA class II-III symptoms despite optimal beta-blocker or calcium channel blocker therapy 8, 9
- Mavacamten improves LVOT gradients, functional capacity, and quality of life in 30-60% of patients with hypertrophic cardiomyopathy, but requires mandatory REMS program monitoring due to the risk of LVEF reduction <50% 8, 9
- Disopyramide, in combination with an AV nodal blocking agent, is an alternative third-line agent for patients with hypertrophic cardiomyopathy who do not respond to beta-blockers and calcium channel blockers 6, 7
Critical Management Pitfalls to Avoid
- The American College of Cardiology recommends discontinuing all vasodilators, including ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, digoxin, alpha-blockers, nitrates, and hydralazine, as they can worsen LVOT obstruction in patients with hypertrophic cardiomyopathy 6, 7
- Dihydropyridine calcium channel blockers, such as nifedipine and amlodipine, are Class III: Harm recommendations for patients with resting or provocable LVOT obstruction, according to the American College of Cardiology 7
Special Populations and Considerations
- For nonobstructive HCM with preserved ejection fraction, beta-blockers or non-dihydropyridine calcium channel blockers are recommended for symptoms of exertional angina or dyspnea, according to the American Heart Association 10
- Valsartan may be beneficial for younger patients (≤45 years) with pathogenic sarcomere variants and mild phenotype to slow adverse cardiac remodeling, with a Class 2b recommendation from the American Heart Association 8, 11
Comprehensive Risk Factor Modification
- Intensive management of cardiometabolic risk factors, such as obesity and hypertension, is essential for patients with hypertrophic cardiomyopathy, as these factors are highly prevalent and associated with poorer prognosis, according to the American College of Cardiology 12
- Obesity management is crucial, as it is present in >70% of adult HCM patients and independently associated with increased left ventricular hypertrophy burden, more symptoms, and worse outcomes 7
Atrial Fibrillation Management
- In patients with HCM and clinical atrial fibrillation, anticoagulation is recommended with direct-acting oral anticoagulants as first-line option, independent of CHA₂DS₂-VASc score, according to the American Heart Association 10